HIV-1 infection is associated with dramatic alteration in gut microbiome composition. Gut microbiome dysbiosis has been associated with pathologies prevalent in HIV-infected individuals including metabolic disease and chronic inflammation. We and others have shown that the gut microbiome of HIV-infected individuals in the US has decreased proportions of the Bacteroides genus and increased Prevotella. In a currently funded R01, we are exploring whether this Prevotella rich/Bacteroides poor (PrevR/BacP) microbiome is related to metabolic disease in HIV patients, specifically lipodystrophy. One factor that complicates the notion that a PrevR/BacP microbiome is related to disease, is that it is also common in health. We have shown that fecal microbiome composition of HIV-positive individuals in the US is strikingly similar to that of healthy individuals in Agrarian populations in Malawi and Venezuela. In the US, individuals with a related PrevR/BacP gut microbiome comprise ~18% of healthy adults and consume diets rich in carbohydrates and low in animal products. Our overarching hypothesis is that HIV-1 infection disrupts adaptive immune responses in the gut that are crucial for promoting colonization of protective bacteria in the context of a Western High Fat Diet (HFD), resulting in a diet/microbiome mismatch which in turn leads to local and systemic inflammatory responses and metabolic disease. We will investigate this hypothesis by conducting three Specific Aims. First, we will examine the relationship between fecal microbiome composition, diet, and inflammatory/metabolic disease markers in HIV-infected subjects pre and post antiretroviral therapy (ART) and HIV-negative controls in rural and urban Zimbabwe using high-throughput 16S ribosomal RNA (rRNA) targeted gene sequencing. This will be the first study to evaluate rural and urban populations in sub-Saharan Africa where the majority of the world's HIV-infected individuals reside and will begin to produce an understanding of how a Westernization of diet in urban centers in the developing world may influence HIV pathogenesis and metabolic co-morbidity. Second, we will assess the effect of short-term diet modification with Agrarian versus Western-like diets on microbiome composition and inflammatory/ metabolic disease markers in ART-treated HIV-infected subjects and HIV-negative controls in the US. This will help to determine whether dietary modulation may be an effective strategy for treating metabolic/inflammatory co-morbidities in HIV-patients. Third, we will examine the role of IL-10 producing CD4+ T regulatory cells (Tregs/Tr1) in microbiome compositional changes that occur with HIV-infection and systemic inflammation. This will help to elucidate driving factors for and consequences of the microbiome changes that occur with HIV infection. The findings from this study could have far reaching implications that extend well beyond HIV infection, by shedding light on how diet and the immune system interact to shape gut microbiome composition in health and disease.

Public Health Relevance

This study will determine the effects of a Western high fat diet (HFD) on the HIV-associated gut microbiome and inflammatory/metabolic co-morbidities, by studying individuals in rural and urban Zimbabwe who are expected to consume relatively Agrarian versus Western diets, and in individuals in the US who are consuming controlled Agrarian versus Western-type diets during a 4 week diet intervention. We will also examine the role of IL-10 producing CD4+ T regulatory cells (Tregs/Tr1) in microbiome compositional changes that occur with HIV-infection and systemic inflammation. Taken together, this will address the hypothesis that HIV-1 infection disrupts adaptive immune responses in the gut that are crucial for promoting colonization of protective bacteria in the context of a Western HFD resulting in a diet/microbiome mismatch which in turn leads to local and systemic inflammatory responses and metabolic disease, and will allow for assessment of how diet modulation will effect HIV-related morbidity in both the US and Africa

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK108366-01
Application #
9050104
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (O2))
Program Officer
Perrin, Peter J
Project Start
2015-09-21
Project End
2020-08-31
Budget Start
2015-09-21
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$600,187
Indirect Cost
$187,896
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Neff, Charles Preston; Krueger, Owen; Xiong, Kathy et al. (2018) Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals. EBioMedicine 30:192-202
Lozupone, Catherine A (2018) Unraveling Interactions between the Microbiome and the Host Immune System To Decipher Mechanisms of Disease. mSystems 3:
Palmer, Brent E; Li, Sam X; Lozupone, Catherine A (2016) The HIV-Associated Enteric Microbiome Has Gone Viral. Cell Host Microbe 19:270-2
Li, S X; Armstrong, Ajs; Neff, C P et al. (2016) Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy. Clin Pharmacol Ther 99:600-11